Гинекология
Международные клинические данные по гирудотерапии при воспалительных заболеваниях органов малого таза, эндометриозе и гинекологических состояниях
Gynecologic indications are investigational (Tier C). See How Evidence Is Graded for the tier framework and Coverage Map for an organ-system view.
Off-label — это показание не разрешено FDA
Разрешённое показание: Gynecological applications (parametritis, adnexitis, endometriosis, salpingo-oophoritis)
Off-label назначение законно в США и остаётся клиническим решением. Обсуждение ниже приводится в образовательных целях и не является разрешённым FDA показанием.
Исследовательское применение
Международные клинические данные
Gynecological applications represent one of the most extensively documented hirudotherapy domains, with data spanning six decades (1944-2003) and over 700 patients across 19 investigations. The evidence includes two controlled trials (Gelman, 1962, n=155; Khardikov et al., 2003, n=50) and one Western case report (Tissot-Guerraz et al., 1987). No randomized controlled trials exist for any gynecological indication.
Биологическое обоснование
Inflammatory diseases of the female reproductive organs feature microvascular compromise within pelvic venous and lymphatic plexuses, peritoneal adhesion formation, and chronic tissue edema. Infection damages endothelial integrity, activates local coagulation, and impairs drainage, creating a self-perpetuating cycle of congestion, hypoxia, and fibrosis. Conditions such as endometriosis and tubal obstruction share overlapping vascular and fibrotic pathophysiology.
Противовоспалительный
Eglins and bdellins inhibit elastase, cathepsin G, trypsin, and plasmin, attenuating neutrophil-mediated tissue damage central to parametritis, adnexitis, and endometriosis.
Антимикробный
Destabilase-L provides bactericidal lysozyme activity against gram-positive pathogens (S. aureus), relevant to puerperal infections, mastitis, and vaginal dysbiosis.
Деконгестивный
Hyaluronidase facilitates edema drainage and enhances tissue permeability, addressing lymphatic congestion that perpetuates chronic pelvic inflammation and adhesions.
Антикоагулянтный
Hirudin, calin, and saratin address the hypercoagulable microenvironment in pelvic inflammation, where microthrombosis contributes to tissue ischemia and fibrosis.
Анальгетический
Kininases degrade bradykinin locally, providing analgesia particularly relevant to chronic pelvic pain and endometriosis-associated pain syndromes.
Антиадгезивный
Hyaluronidase, proteinase inhibitors, and microcirculatory enhancement collectively target the adhesion cascade in tubal obstruction and endometriosis.
Клинические доказательства
Sixteen studies investigated gynecological hirudotherapy. All originate from Russian/Eastern European centers (1944-2003) except one French case report. The two controlled trials (Gelman, 1962; Khardikov et al., 2003) provide the strongest evidence.
Уровень доказательности GRADE: Низкий
Наблюдательные исследования или РКИ с серьёзными ограничениями
| Исследование | Дизайн | Популяция (n=) | Вмешательство | Ключевой исход | Результат |
|---|---|---|---|---|---|
| Gelman 1962 | Controlled trial | Parametritis / adnexitis (n=155) | HT+penicillin (n=67) vs controls (n=88) | Sustained improvement at 12-18 mo | 76% vs 25% sustained improvement Largest controlled gynecological trial |
| Khardikov et al. 2003 | Controlled trial | Chronic salpingo-oophoritis (n=50) | HT+therapy (n=20) vs controls (n=30) | Blood flow, inflammatory resolution | 80% vs 40% resolution (p<0.01) |
| Gromova 2000 | Case series | Acute/chronic salpingo-oophoritis (n=70) | HT adjunct to pharmacotherapy | Pain, well-being, functional capacity | Accelerated recovery at all stages |
| Zhivoglyad & Nikonov 1998 | Case series | Endometriosis (n=40) | 12 sessions; up to 140 MLs per course | Ultrasound assessment | 60% no residual endometriosis on US Min 102 MLs recommended |
| Startseva et al. 2001 | Case series | Endometriosis (refractory) (n=41) | Intravaginal+external; 2-3 courses | Pain, blood loss, fertility | 90% reduced bleeding; 4 pregnancies |
| Kurgina 2000 | Case series | Bacterial vaginosis (n=28) | 2-5 MLs q1-2d; 10-15 sessions | Clinical/microbiological cure | complete clinical response in all 28 patients; full lactobacillus restoration 11 monotherapy; 17 HT+metronidazole |
| Batoev 1999 | Case series | Hydrosalpinx (prior failure) (n=20) | Monotherapy; 4-6 sessions | US assessment | 80% undetectable; 20% decreased |
| Platonov 1998 | Case series | Postpartum wounds/cesarean (n=95) | MLs to suture infiltrate sites | Infiltrate resolution | Good response; improved microcirculation |
| Galchenko & Shkolny 1969 | Case series | Chronic adnexitis (n=25) | 4-5 MLs posterolateral fornices | TEG, pain, mobility | TEG correction; increased mobility |
| Chaban et al. 1995 | Mixed case series | Gynecological diseases (n=73) | HT+standard treatment | Clinical improvement | Effective; alternative to surgery for myomas |
| Tissot-Guerraz et al. 1987 | Case report | Purulent mastitis (n=1) | ML application to breast | Infection resolution | Successful; antibacterial effect Only Western-published case |
Параметрит и аднексит — детальные результаты
The most extensively documented indication, with five studies spanning 1944-1969. Parametritis begins with infection penetrating venous and lymphatic plexuses, progressing to parametrial tissue involvement and potential abscess formation.
Gelman (1962) conducted the largest controlled trial: 3-5 leeches every 4-5 days to the vaginal fornix with 16-hour tamponade. At 12-18 months, 76% of the HT group showed sustained improvement versus 25% of controls. Shvets (1967) documented rapid improvement (temperature, pain, ESR) with no systemic coagulation effect. Galchenko & Shkolny (1969) provided objective TEG documentation of coagulation correction.
Сальпингоофорит — детальные результаты
Khardikov et al. (2003) studied chronic salpingo-oophoritis: HT group (n=20) vs controls (n=30). HT produced more pronounced pelvic blood flow improvement (p<0.01). Resolution: 80% HT vs 40% controls; significant regression in 20% vs 50%; 10% of controls showed no improvement.
Gromova (2000) observed 70 patients with acute/chronic disease. HT accelerated pain relief, well-being improvement, and functional capacity restoration. Recommended at four stages: infiltrative, subsiding acute, chronic, and during complications.
Эндометриоз — детальные результаты
Живогляд и Никонов (1998)
- Protocol: 12 sessions; up to 140 leeches (min 102)
- Sites: Anal triangle, Petit's triangle, abdominal wall
- Result: 60% no residual endometriosis on US; 40% improved
Старцева и др. (2001)
- Protocol: 15-20 MLs/course, 10-12 days; 2-3 courses
- Sites: Intravaginal (fornices) + external (pubic, perianal)
- Result: 90% reduced bleeding; 4 infertile women conceived
Бактериальный вагиноз и гидросальпинкс
Бактериальный вагиноз — Кургина (2000)
complete clinical response in all 28 patients (28/28) with complete lactobacillus restoration. Eleven monotherapy; 17 HT+metronidazole. Applied to vaginal mucosa, cervix, abdominal wall, coccyx, liver projection; 2-5 MLs q1-2d, 10-15 sessions. Suggests dysbiosis correction rather than pathogen suppression.
Гидросальпинкс — Батоев (1999)
80% undetectable on US (16/20) after 4-6 sessions of monotherapy; 20% showed decreased size. All patients had failed prior conventional treatments. Applied to perineum, fornices, anal rhombus, abdominal wall, sacrum.
Бесплодие, послеродовые осложнения и другие показания
Infertility: Across four observations, 10/34 previously infertile women (29%) conceived: Gromova (2000) 5/12; Startseva et al. (2001) 4 endometriosis patients; Kurgina (2000) 1/3. Results support biological plausibility through adhesion resolution and microcirculation improvement.
Postpartum: Three studies (~165 patients) showed rapid infiltrate resolution, pain reduction, and reduced post-cesarean complications (Platonov 1998; Batoev 1999; Gazazyan & Khardikov 2003).
Mixed series: Chaban et al. (1995, n=73) concluded HT effective for inflammatory conditions and a rational surgical alternative for myomas. Tissot-Guerraz et al. (1987) resolved purulent mastitis via destabilase-L activity — the only Western-published gynecological HT case.
Клинический протокол
Воспалительные показания
- Parametritis / adnexitis — adjunct to antimicrobials
- Salpingo-oophoritis — adjunct to pharmacotherapy
- Postpartum endometritis, suture infiltrates, metrophlebitis
- Infected perineal tears / post-cesarean wounds
- Purulent mastitis — adjunct to antimicrobials
Невоспалительные показания
- Bacterial vaginosis — monotherapy or adjunct
- Hydrosalpinx — monotherapy after conventional failure
- Endometriosis — pain, menstrual dysfunction, refractory
- Tubal / endocrine infertility — adjunct
- Uterine fibroids / myomas — adjunct or surgical alternative
До процедуры
- Microbiological diagnosis (cultures, bacterioscopy, vaginal pH); initiate antimicrobials as indicated
- Baseline pelvic ultrasound for structural conditions
- Complete coagulation profile; review anticoagulant/antiplatelet medications
- CBC baseline for multi-session courses
- Rule out pregnancy and pelvic malignancy
Места приложения
- Vaginal fornices (posterior/lateral): Adnexitis, salpingo-oophoritis, endometriosis — proximity to adnexa
- Anterior abdominal wall (suprapubic): Parametritis, endometriosis, postpartum — projection over pelvic organs
- Cervix / vaginal mucosa: Bacterial vaginosis, cervicitis — direct mucosal contact
- Perineum: Hydrosalpinx, endometriosis, perineal tears — perineal plexus access
- Lumbosacral / sacrum / coccyx: Postpartum, endometriosis — reflex zone; pelvic lymphatic drainage
- Anal rhombus / Petit's triangle: Hydrosalpinx, endometriosis — deep pelvic venous drainage
- Inguinal fold: Postpartum — pelvic lymphatic/venous drainage
- Right hypochondrium (liver): Vaginosis, hydrosalpinx — hepatic portal decongestive effect
Параметры дозирования
- Standard: 2-7 leeches/session; full exposure; 1-2x/week (parametritis q4-5d; vaginosis q1-2d); 3-12 sessions per course
- Endometriosis: 15-20 MLs per course over 10-12 days; 10-12 sessions; 2-3 repeat courses; up to 140 total MLs (min 102 for extensive disease)
После процедуры
- Tamponade removal at 16 hours; monitor oozing (4 to 24 hours expected)
- Follow-up ultrasound at course completion for structural conditions
- Reassess pain, temperature, ESR, pelvic mobility every 2-3 sessions
- CBC at mid-course and completion (cumulative blood loss detection)
- Repeat cultures for bacterial vaginosis at course end
Вопросы безопасности
- Pelvioperitonitis (ABSOLUTE): Risk of sepsis generalization and DIC; SGS anticoagulants exacerbate coagulopathy (Yakimova, 1999).
- Acute septic endometritis (ABSOLUTE): Same DIC/sepsis risk. Distinguish treatable infiltrative/subacute stages from contraindicated septic states.
- Active hemorrhage: SGS anticoagulant/antiplatelet properties exacerbate bleeding.
- Pregnancy: Relative contraindication.
- Suspected malignancy: Tissue diagnosis first; local application may enhance neoplasm blood flow.
Риск по стадиям
Indicated: Infiltrative stage (promotes resolution), subsiding acute (accelerates resolution), chronic course (addresses fibrosis and adhesions). Case-by-case: Complication stage (suppuration may respond; peritonitis contraindicated). Contraindicated: Acute septic phase and pelvioperitonitis (DIC/sepsis risk; Yakimova, 1999).
Лекарственные взаимодействия
| Препарат | Взаимодействие | Действие |
|---|---|---|
| Anticoagulants | Additive (hirudin, calin, saratin, apyrase) | Careful monitoring; dose adjustment |
| Antiplatelet agents | Additive platelet inhibition | Individual risk-benefit assessment |
| Antimicrobials | No adverse interactions | Continue as indicated |
| Hormonal therapy / OCP | Theoretical estrogen-thrombotic concern | Standard precautions |
Мониторинг
- Coagulation: Baseline and periodic (especially endometriosis extended courses)
- CBC: Cumulative blood loss; critical for hyperpolymenorrhea patients
- Ultrasound: Baseline and course completion for structural conditions
- Clinical: Pain, temperature, ESR every 2-3 sessions
- Microbiology: Repeat cultures for vaginosis at course end
Пробелы в доказательной базе и приоритеты исследований
Despite 700+ patients across six decades, the evidence has significant limitations: no RCTs, all data from Russian/Eastern European centers, variable outcome measures, and combined interventions limiting attribution.
- Chronic salpingo-oophoritis: RCT with pelvic Doppler and inflammatory markers
- Bacterial vaginosis: Controlled comparison with microbiome analysis
- Endometriosis pain: Pilot with VAS and EHP-30 endpoints
- Hydrosalpinx: Prospective cohort with serial US and hysterosalpingography
- Reproductive outcomes: Prospective fertility registry
Ключевые выводы
Controlled trial data: Three-fold improvement in parametritis (76% vs 25% at 12-18 mo) and two-fold in salpingo-oophoritis (80% vs 40%, p<0.01) across two non-randomized controlled trials.
Microbiome restoration: complete clinical response in all 28 patients with full lactobacillus restoration in bacterial vaginosis (n=28), suggesting dysbiosis correction rather than pathogen suppression.
Critical contraindications: Pelvioperitonitis and acute septic endometritis are absolute contraindications (DIC/sepsis risk). Stage-appropriate patient selection is fundamental.
Endometriosis protocols: Most intensive in the literature (up to 140 leeches, 12 sessions, 2-3 courses). 60% no residual US findings; 90% reduced bleeding; 4 pregnancies in infertile women.
Hydrosalpinx monotherapy: 80% undetectable on US after 4-6 sessions in patients who had failed all prior conventional treatments (n=20).
Investigational status: All gynecological applications are off-label in the US. Evidence is Level III-IV from Russian/Eastern European centers. RCTs needed.
Список литературы
- Batoev, Ts. Zh. (1999). Hirudotherapy in postpartum complications.
- Batoev, Ts. Zh. (1999a). Hirudotherapy for hydrosalpinx (n=20).
- Bornshtein, I. A. (1952). Leeches in acute pelvic inflammation.
- Chaban, T. N., Kapralova, M. V., & Savinov, V. A. (1995). HT in 73 gynecological patients.
- Galchenko, G. I., & Shkolny, V. N. (1969). TEG changes in chronic adnexitis.
- Gazazyan, M. G., & Khardikov, A. V. (2003). HT after cesarean section.
- Gelman, I. G. (1962). Comparative study in parametritis/adnexitis (n=155).
- Gromova, O. A. (2000). HT in salpingo-oophoritis and infertility (n=70).
- Khardikov, A. V., et al. (2003). Controlled study, chronic salpingo-oophoritis (n=50).
- Kurgina, L. S. (2000). HT for bacterial vaginosis (n=28).
- Lukyanova, E. A. (1999). HT for tubal infertility.
- Platonov, A. V. (1998). HT in postpartum wound healing (n=95).
- Shamilev, R. V., & Kulanin, G. V. (2001). Sanatorium gynecological HT.
- Shpolyansky, B. A. (1944). HT in parametritis (n=15).
- Shvets, V. N. (1967). Leeches in parametritis treatment.
- Startseva, N. V., et al. (2001). HT for endometriosis (n=41).
- Tissot-Guerraz, F., et al. (1987). Leech treatment of purulent mastitis.
- Yakimova, T. P. (1999). Contraindications for gynecological HT.
- Zhivoglyad, R. N., & Nikonov, G. I. (1998). HT for endometriosis (n=40).
Связанные ресурсы
Клинические специальности
Обзор 14 медицинских специальностей.
Эндокринология
Перекрывающиеся климактерические и метаболические применения.
Хирургия
Послеоперационные применения и заживление ран.
Ингибиторы протеиназ
Эглины, бделлины, LDTI — противовоспалительные соединения.
Все показания
Полный список показаний с уровнями доказательности.